Clonal Cytogenetic Abnormalities After Tyrosine Kinase Inhibitor Therapy in Ph+ ALL Resolution After Decitabine Therapy
Overview
Oncology
Pediatrics
Affiliations
Mixed chimerism and presence of minimal residual disease after stem cell transplantation (SCT) usually predict leukemia recurrence. In Philadelphia chromosome positive (Ph+) leukemia tyrosine kinase inhibitors can restore remission. These agents can induce clonal cytogenetic abnormalities in the Philadelphia negative cell population (CCA/Ph-), which may rarely progress to acute myeloid leukemia. A child with Ph+ acute lymphoblastic leukemia showed mixed donor chimerism and persistent bcr-abl transcripts after a matched sibling SCT. There was no response to tyrosine kinase inhibitor (TKI) therapy, but she has remained hematologically normal for more than 5 years. CCA/Ph- was detected but resolved with hypomethylating therapy.
Liu J, Jiang Z, Xie X, Wan D, Cao W, Wang M Front Oncol. 2021; 11:710545.
PMID: 34485147 PMC: 8415411. DOI: 10.3389/fonc.2021.710545.